Zymeworks (ZYME) Amortization of Deferred Charges (2026)
Zymeworks (ZYME) posted Amortization of Deferred Charges of $26000.0 for Q1 2026, down 97.19% sequentially from $924000.0 in Q4 2025, and down 96.32% YoY from $707000.0 in Q1 2025.
Analysis
Zymeworks (ZYME) Amortization of Deferred Charges (2026) Analysis & Trends
Zymeworks has reported Amortization of Deferred Charges for 6 years, with the latest figure at $26000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges fell 96.32% year-over-year to $26000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 1.39% YoY) and the FY2025 annual result came in at $3.4 million, up 34.91% from the prior year.
- Amortization of Deferred Charges declined to $26000.0 in Q1 2026 per ZYME's latest filing, from $924000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $3.5 million in Q3 2023 and troughed at $26000.0 in Q1 2026.
- A 5-year average of $1.0 million and a median of $690000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2023 and 2026: Amortization of Deferred Charges surged 440.03% in 2023, then sank 96.32% in 2026.
- Over 5 years, Amortization of Deferred Charges stood at $627000.0 in 2022, then soared by 81.66% to $1.1 million in 2023, then plunged by 39.42% to $690000.0 in 2024, then soared by 33.91% to $924000.0 in 2025, then tumbled by 97.19% to $26000.0 in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $26000.0, $924000.0, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - |